Catherine Gregor, MBA, CCRC, CCRP CRC Workshop August 1, 2014

Slides:



Advertisements
Similar presentations
Tips to a Successful Monitoring Visit
Advertisements

The Principal Investigator’s Roles and Responsibilities Chicken Soup for the Busy Coordinator (May 2010)
Research Study Regulatory Binder Ronald Cowan, MD, PhD J. Gavin Lillevig, BS Summer Professional Didactics Data Management Psychiatric Neuroimaging Program.
Managing Regulatory Documents Electronically
Research Coordination Guidance The Committees on Human Research Serving University of Vermont & Fletcher Allen Health Care
UTHSC IRB Donna Hollaway, RN, CCRC 11/30/2011 Authority to Audit 45 CFR (e) An IRB shall conduct continuing review of research covered by this.
David Cloutier Director, Research Center Management and Development Budgeting for Industry Sponsored Clinical Trials.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
Pharmacists Responsibilities in Clinical Studies Mike R Sather, PhD Crystal L Harris, PharmD February 26, 2004.
John Naim, PhD Director Clinical Trials Research Unit
Stanley Estime, MSCI December 9, 2014 Record Keeping: What is Regulatory Documentation and how should it be maintained? Tel:
Research and Development Protocol Submission and Continuing Review Processes Kimberly Summers, PharmD Assistant Chief for Clinical Research South Texas.
Janet Ellen Holwell, CCRC, CCRA President, NY Metropolitan Chapter of ACRP.
Planning and Surviving An Audit/Monitoring visit Carmen B. Jacobs, BS, RN,OCN, CCRP U.T. MD Anderson Cancer Center Houston, Texas U.S.A.
Investigational New Drug Application (IND)
Common Audit Findings UTHSC Institutional Review Board (IRB)
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
Monitoring IRB Monitoring of Clinical Trials. Types of Monitoring Internally Internally Externally Externally.
CLINICAL TRIALS – PHASE III. What are phase III trials  Confirmatory phase (Therapeutic confirmatory trial)  Trials are done to obtain sufficient evidence.
1 January 17, 2008 Test Article Accountability. 2 January 17, 2008 Investigator Responsibilities 21 CFR  Maintain control of drug under investigation.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
AUDIT REQUIREMENTS, FINDINGS & BASICS RESEARCH COMPLIANCE.
Copyright FDA Inspections: Where Do Things Go Wrong? Diana Naser RN, MS, CCRP Executive Director Clinical Research Administration Clinical Research.
Stanley Estime, MSCI October 19, 2015 Record Keeping: What is Regulatory Documentation and how should it be maintained? Tel:
Office of Human Research Protection Georgia Health Sciences University.
IP Accountability in Outpatient Clinical Trials
Sponsor Visits and Monitoring
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
Research Documentation Betty Wilson, CIP, MS Senior Compliance Manager MU IRB Lori Wilcox, EdD Director of Academic Compliance, Corporate Compliance.
IRB BASICS BETTY WILSON, MS, CIP. CONCEPTS SUBMISSION APPROVAL RECRUITING WORKING WITH PRINCIPAL INVESTIGATOR (PI) /SPONSOR POLICIES DEVIATIONS RECORD.
Session 2 IRB Training  What is the Principal Investigator’s role in Human Subject Research?  What is the role of the Investigator’s staff in Human Subject.
Slide 1 Standard Operating Procedures. Slide 2 Goal To review the standard operating procedures Creating the informed consent document Obtaining informed.
Responsibilities of Sponsor, Investigator and Monitor
IP Accountability in Outpatient Clinical Trials Jessica Rinaldi, CCRP Farber Institute for Neurosciences.
Data Management: Source Documents, Case Report Forms and Electronic Data Thomas Salerno, RN BSN MA Senior Team Lead Cardiology Research Jefferson Clinical.
Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
Supervisory Responsibilities of Clinical Investigators
Good Clinical Practice (GCP) and Monitoring Practices
Instructions for New IRB Continuing Review (Progress) Report
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
The Role and Responsibilities of the Clinical Research Coordinator
Preparing for and Handling Monitoring Visits and Audits
Stephanie Oppenheimer, MS SUCCESS Center Erica Ellington, CRA, CHRC
Responsibilities of Sponsor, Investigator and Monitor
MAINTAINING THE INVESTIGATOR’S SITE FILE
IRB reporting updates.
Investigator of Record – Definition
Alyssa Speier, MS, CIP November 13, 2013
Reasons for Auditing There are many reasons for auditing. Some examples of these reasons might be: Requested by the IRB Committee Requested by an IRB.
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Patient Medical Records
Roles and Responsibilities of the Clinical Research Team
Regulatory Binder: Maintaining Essential Study Documentation
Elements of an Organized Regulatory Binder
Basics of Building and Understanding Data Collection Forms
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
The HIPAA Privacy Rule and Research
Investigator of Record – Definition
MAINTAINING THE INVESTIGATOR’S STUDY FILE
Monitoring, Auditing and Compliance
Event Reporting in Human Subjects Research
Understanding the Process of Documenting Informed Consent
Quality Assurance in Clinical Trials
Protocol Approval Criteria
Good clinical practice
Presentation transcript:

Catherine Gregor, MBA, CCRC, CCRP CRC Workshop August 1, 2014 Source Documentation Catherine Gregor, MBA, CCRC, CCRP CRC Workshop August 1, 2014

Which of these Study Documents are considered Source documents? Regulatory Binder Medical Record Case Report Form Participant File 7/25/2014 2

Source Data The ICH E6 document, section 1.51, defines source data as "All information in original records and certified copies of original records or clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Source data are contained in source documents (original records or certified copies)." Source Documents The ICH E6 document, section 1.52, defines source documents as "Original documents, data and records (e.g., hospital records, clinical and office charts, laboratory notes, memoranda, subjects' diaries of evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate and complete, microfiches, photographic negatives, microfilm or magnetic media, x-rays, subject files, and records kept at the pharmacy, at the laboratories, and at medico-technical departments involved in the clinical trial)."

Simple enough right? But what about Case report forms?

When Do Case Report forms become source? If allowed by the investigational plan (protocol), data may be entered directly onto the case report forms. The case report form would then be considered a source document. If this case report form is then transmitted to the sponsor, it is necessary for the study site to retain a copy to ensure that the principal investigator can provide access to the source documents to a monitor, auditor, or regulatory agency. Additional information can be found in ICH E6, section 6.4.9.

Why do we need source Documents? Data collected in research studies may be useless without adequate and accurate documents Data that is suspect or cannot be verified may be thrown out Source documents assist researchers in assuring that each study is compliant with IRB policies and other federal regulatory authorities If we cant replicate it then it didn’t happen…… 7/25/2014 6

What are the regulations and policies that govern research documentation at Vanderbilt? 7/25/2014

For any human subjects research conducted at Vanderbilt: 45 CFR 46 Documentation of IRB approval Documentation of informed consent Documentation of management of vulnerable populations in accordance with regulations IRB policies Documentation of compliance with protocol (inclusion/exclusion, study procedures) Documentation of adverse event reporting Documentation of appropriate staff training/qualifications Documentation of compliance with federal, state and institutional regulations/policies

For FDA regulated studies at Vanderbilt 21 CFR 312 For FDA regulated studies at Vanderbilt 21 CFR 312.62 for drugs and 21 CRF 812.140 for devices (a)Disposition of drug. An investigator is required to maintain adequate records of the disposition of the drug, including dates, quantity, and use by subjects. If the investigation is terminated, suspended, discontinued, or completed, the investigator shall return the unused supplies of the drug to the sponsor, or otherwise provide for disposition of the unused supplies of the drug under 312.59. (b)Case histories. An investigator is required to prepare and maintain adequate and accurate case histories that record all observations and other data pertinent to the investigation on each individual administered the investigational drug or employed as a control in the investigation. Case histories include the case report forms and supporting data including, for example, signed and dated consent forms and medical records including, for example, progress notes of the physician, the individual's hospital chart(s), and the nurses' notes. The case history for each individual shall document that informed consent was obtained prior to participation in the study. 7/25/2014

“The protocol specified that study drugs were to be prepared by the pharmacist or designee who was trained in the safe handling and administration of a cytotoxic agent. The Infusion Preparation Log for Subject 040-001 documents that study drugs were prepared on March 24 by an individual identified only by the initials [JKM]. There was no documentation in the study records that [JKM] was the pharmacist or designee, or that [JKM] had been trained in the safe handling and/or administration of a cytotoxic agent.” –FDA Warning Letter    You failed to personally conduct or supervise the clinical investigation. You failed to ensure that the investigation was conducted according to the investigational plan. You failed to protect the rights, safety, and welfare of the subjects under your care. All of the above. None of the above. 7/25/2014

So where does one begin?

Regulatory Binder: Protocol, all versions Investigators brochures, all versions Clean case report forms, all versions Consent forms, all versions Advertising and recruitment materials, all versions (approval required) 1572, all versions CVs, current copies for everyone listed on 1572 Verification of staff training Financial Disclosure/Conflict of interest statement Lab certifications, reference values, and deliveries 7/25/2014 12

Regulatory Binder (cont) 1. IRB submissions Original submission Continuing reviews Amendments Adverse Events- local and non- local safety reports Non-compliance with the protocol (may include items that did not require IRB submission) 2. Keep copies of all submissions, approvals, and correspondence 7/25/2014 13

Regulatory Binder (cont) Signature/delegation of responsibilities log Screening and enrollment logs Drug/device records (may be maintained by the pharmacy if IDS is utilized) Monitoring Logs Correspondence Telephone logs Notes to file Miscellaneous 7/25/2014 14

A word about notes to file… Should not be used exclusively as devices to explain discrepancies Should not be used exclusively to explain missing or incomplete data Do Not replace “adequate and accurate case histories” (21 CFR 312.62) Are Increasingly requested by sponsor monitoring staff - not generally temporally associated Can be Red Flags

Notes to file the right way….. Be generated on a case-by-case basis Include the subject and protocol it refers to Be signed and dated by the individual who is writing it Be legible if handwritten Explain clearly and specifically the reason for the error/omission/discrepancy or process/policy it aims to address. Should include any corrective and preventative action or follow-up when applicable. Be filed with the document, subject file or behind the study binder tab to which it applies

Regulatory Binder (cont) What not to include: Quality Assurance review findings Personnel issues Invoices to sponsor Contract 7/25/2014 17

Tip for maintaining Study Documents Maintain papers on a regular basis—don’t let a mole hill turn into a mountain. Set time once a week to make sure your binders are in order. 7/25/2014 18

What is a Participant File? A file containing the study documents pertaining to an individual participant in your study The participant file should contain all information needed to reconstruct a participant’s activities on study 7/25/2014 19

What should be in Participant files? Original signed consent form Case report form Questionnaires Records of materials and drugs given to participant, drugs returned Medical history Record of study visits Physician notes Memos to file Adverse Events Diaries Communications (emails and phone calls)

Source Document Tips Do: Don’t: No white-out No pencil No back-dating Have signature lines for portions of your CRF that are used as source documentation Date and initial all notations Use blue or black pen Correct errors with a single strike through, date and initial Include the subject ID on all pages in record Use subject ID instead of names to protect patient privacy Keep files in locked cabinet/room Don’t: No white-out No pencil No back-dating 7/25/2014 21

Case report forms are used in order to collect data in a standardize way and ensure that all data elements are captured. Data are recorded on the forms for each subject in the study and then entered/transfered into a database. Case Report Forms 7/25/2014 10/14/2018 22

Case Report Forms Generally Includes: Inclusion/Exclusion criteria Demographic information Medical history Medications Lab tests Clinical endpoints and outcomes Adverse events Study summary and PI evaluation **If you are developing your own CRF, be sure to pilot it before beginning enrollment. Poorly designed CRFs result in poorly collected data. 7/25/2014

Study Closeout-how long should you maintain study records? Drug or device studies: Two years AFTER the drug approval was granted or denied OR the length of time stated in the contract with the sponsor – whichever is greater HIPAA requires 6 years after study closure Behavioral and Social Science studies: Three years AFTER the study has been closed with the IRB Archive, Archive, Archive ASK BEFORE DESTROYING ANYTHING 7/25/2014 24

Key Points Remember, organizing your paperwork can be as important as dispensing the right drug. Researchers protect human subjects by having paperwork in order. Don’t have multiple collection “dumps” Remember your patients confidentiality—use names as minimally as possible. Keep files in locked cabinet/room. 7/25/2014 25

Questions?